ArticleCureus2026
Plasma Cystatin C as a Marker of Acute-on-Chronic Liver Failure and 28-Day Mortality in Patients With Acutely Decompensated Liver Cirrhosis: A Prospective Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute decompensation of cirrhosis carries a 28-day mortality of 1.9%, rising to nearly 30% with acute-on-chronic liver failure (ACLF), in which renal failure is the most frequent and most ominous organ failure. Serum creatinine overestimates glomerular filtration rate in cirrhosis. Plasma cystatin C may better reflect renal function and prognosis, but Indian data are scarce. We assessed cystatin C as a marker of ACLF and 28-day mortality in acutely decompensated cirrhosis.
methodsIn this prospective observational cohort study, 100 adults with acutely decompensated cirrhosis were enrolled over 18 months. We performed clinical assessments and standard investigations, and measured plasma cystatin C by nephelometric immunoassay within 48 hours of admission. Participants were followed for ACLF and 28-day mortality. Cystatin C, Child-Turcotte-Pugh (CTP), and Model for End-Stage Liver Disease (MELD) scores were compared as predictors of mortality by receiver operating characteristic (ROC) curve analysis.
resultsACLF developed in 41 participants (41%), and 44 (44%) died within 28 days. Mean plasma cystatin C was higher in non-survivors than survivors (5.49±4.70 vs 2.06±1.54 mg/L; p<0.001) but did not differ by ACLF status (p=0.271). Cystatin C predicted 28-day mortality with AUROC 0.781 (95% CI 0.688-0.874); a cut-off ≥2.5 mg/L gave 73% sensitivity and 75% specificity, outperforming CTP (0.506) and MELD (0.508) scores (p<0.001).
conclusionsPlasma cystatin C rose in patients who died within 28 days and predicted short-term mortality better than CTP or MELD scores, although it did not discriminate ACLF status. Cystatin C may serve as a simple, reproducible adjunct for prognostication in decompensated cirrhosis; larger multicentric studies are needed to validate this cut-off.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.